Axiogenesis’ current focus lies on preclinical drug discovery and drug safety through the development of functional assays using human neuronal and cardiac cells, although it is expanding into new areas.
In the infographics below, Axiogenesis presents the preclinical applications possible with induced pluripotent stem cells (iPSCs), as well as cell types that can be produced from human iPSC cells.
Click on the images below to expand them to their full size.
The next infographic features cell types that can be derived from human iPSCs, including cell types offered by Axiogenesis.
Axiogenesis’ flagship offering is its Cor.4U human cardiomyocyte product family, including cardiac fibroblasts. Cor.4U cells are used in applications for single cell analysis to high-throughput screening (HTS) in early cardiac safety and safety assessment, as well as in cardiovascular drug development.
In the neural field Axiogenesis is offering various iPSC-derived neuronal sub-types including dopaminergic neurons (Dopa.4U), peripheral neurons (Peri.4U), CNS neurons (CNS.4U) and astrocytes (Astro.4U). Sensory neurons, beta islet cells and skeletal muscle cells are in development.
Axiogenesis also offers licensing of proprietary disease models, such as Hypertrophic Cardiomyopathy (HCM), and tissue models for compound screening, as well as value-added fee-for-service assays for in vitro toxicology, safety pharmacology and drug discovery.
Click the infographic below to expand it to its full size.
To learn more about Axiogenesis’ human iPSC products, visit Axiogenesis.com.
About BioInformant
BioInformant is the first and only market research firm to specialize exclusively in the stem cell industry. BioInformant research has been cited by major news outlets that include the Wall Street Journal, Nature Biotechnology, Medical Ethics, Vogue Magazine, and more. Serving Fortune 500 leaders that include GE Healthcare, Pfizer, and Goldman Sachs, BioInformant is your global leader in stem cell industry data.